Vericel's MACI supplies most of $85.4m quarter as cell therapy maker lifts outlook
Third-quarter sales rose 26% and the company reported $14.2m in net income, while pointing to a UK debut for its knee cartilage product next year.
Vericel's knee cartilage implant MACI generated almost four-fifths of the company's third-quarter sales, according to results published on 5 November for the period ended 30 September 2026. Total net revenue reached $85.4m, up 26%, and the company booked net income of $14.2m.
MACI contributed $67.4m. The Burn Care business, which houses Epicel and NexoBrid, added $18.0m, roughly a fifth of the total. The split shows how heavily the group's performance rests on a single product.
Management responded to the quarter by raising its financial outlook for 2026. Revenue is now expected to land between $344m and $346m, and the adjusted EBITDA margin target has moved up to 28%. The material available does not give the previous guidance levels, so the size of the upgrade cannot be stated.
Vericel also said it is still working towards bringing MACI to the UK in 2027, though it described this as a potential launch. The information on file contains no detail on the regulatory route, submission status or approval milestones, so how far that process has advanced cannot be confirmed.
Why it matters
- Concentration risk is clear: MACI accounts for about 79% of quarterly revenue, so any supply, quality or regulatory issue with the product would weigh heavily on group results.
- The higher revenue and margin guidance signals management confidence in the rest of 2026, but the earlier targets are not on file for comparison.
- UK payers and commissioners may need to consider a new cartilage repair option if the 2027 plan holds, although the approval timeline has not been disclosed.
- Further detail from Vericel on UK regulatory steps would be needed before the launch timing can be assessed.
Company's press release (SEC filing): Vericel Corp ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
BeyondSpring wins FDA Fast Track for plinabulin-docetaxel in post-immunotherapy NSCLC as cash dwindles to $0.6M
Calidi cuts costs and restructures as Q3 loss reaches $3.6M ahead of CLD-401 IND
Beyond Air reports record $2.3M quarterly revenue as FDA reviews second-generation LungFit PH
DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing
Curis reports Q3 loss of $8.1m as emavusertib trials enrol; cash runway reaches only early 2027
